CAPTRUST Financial Advisors
XERS icon

CAPTRUST Financial Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Buy
19,993
+5,178
+35% +$33.1K ﹤0.01% 2946
2026
Q1 		$85.9K Buy
14,815
+2,999
+25% +$19.9K ﹤0.01% 2830
2025
Q4 		$92.8K Sell
11,816
-88
-0.7% -$693 ﹤0.01% 2620
2025
Q3 		$96.9K Buy
11,904
+1,098
+10% +$7.29K ﹤0.01% 2516
2025
Q2 		$50.5K Sell
10,806
-976
-8% -$4.47K ﹤0.01% 2423
2025
Q1 		$64.7K Buy
+11,782
New +$47.6K ﹤0.01% 2269
2021
Q4 		– Sell
-2,783
Closed -$7K – 4938
2021
Q3 		$7K Sell
2,783
-216
-7% -$627 ﹤0.01% 3824
2021
Q2 		$12K Sell
2,999
-106
-3% -$405 ﹤0.01% 3458
2021
Q1 		$14K Buy
+3,105
New +$16.7K ﹤0.01% 3245

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CAPTRUST Financial Advisors's XERS Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Xeris Biopharma Holdings (XERS) stake by 35% in Q2 2026, buying an estimated $33.1K and bringing the position to 19,993 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #2946.

CAPTRUST Financial Advisors first reported a position in XERS in Q1 2021 and has held it in 9 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • CAPTRUST Financial Advisors held 19,993 shares of Xeris Biopharma Holdings worth $158K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 5,178 Xeris Biopharma Holdings shares in Q2 2026, an estimated $33.1K.
  • Xeris Biopharma Holdings made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2946 holding.
  • CAPTRUST Financial Advisors first reported a position in Xeris Biopharma Holdings in Q1 2021 and has held it in 9 quarters since.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.